Cell Lysis News and Research

RSS

Severe complications from circumcision

A study by Ceylan, et al from Turkey evaluated their experience in 48 cases of severe complications of circumcisions.

14 Apr 2007

Identification of gene in mosquitoes that helps them to fight off infection by the Plasmodium parasite

Researchers have identified a gene in mosquitoes that helps the insects to fight off infection by the Plasmodium parasite, which causes malaria in humans. Anopheles mosquitoes transmit the malaria parasite to nearly 550 million people worldwide each year with these cases resulting in more than 2 million deaths annually.

25 Oct 2005

Anthrax test receives FDA approval

A method for identifying Bacillus anthracis, the causative agent of anthrax, has been cleared for diagnostic use by the U.S. Food and Drug Administration (FDA).

29 Aug 2005

Innovative urine test for highly specific prostate cancer gene shows promise

Gen-Probe's prototype urine test for PCA3 gene expression may help improve the diagnosis of prostate cancer, according to three early-stage studies presented as posters at the American Association for Clinical Chemistry's 37th Annual Oak Ridge Conference and the Annual Meeting of the American Association for Cancer Research (AACR).

20 Apr 2005

Genome clues to amoebic dysentery

Each year, there are an estimated 50 million cases of amoebic dysentery, causing up to 100,000 deaths, mostly in developing countries. On Thursday 24 February 2005, researchers at the Wellcome Trust Sanger Institute and their colleagues reported in Nature magazine the genome sequence of the parasite that causes the disease, Entamoeba histolytica.

1 Mar 2005

Coronary angioplasty within 24 hours of medical therapy could improve the outcome for heart-attack patients

Results of a randomised trial in this week’s issue of THE LANCET suggest that a more aggressive approach involving coronary angioplasty soon after anticlotting medical therapy is safe and could offer a better prognosis than more conservative treatment for patients who have had heart attack.

17 Sep 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004